广告
加载中

血亏200亿 “日本神药”要卖了

李馨婷 2026-10-05 14:01
李馨婷 2026/10/05 14:01

邦小白快读

EN
全文速览

总:这篇报道的核心是小林制药因红曲保健品安全问题遭遇巨额损失、业绩下滑并可能被收购,普通消费者可以从中得到几点重要提醒。

1. 红曲保健品存在健康风险:2024年3月起,部分消费者服用小林制药含红曲成分的保健品后出现肾脏疾病,截至2026年8月底被认定为补偿对象的消费者约520人,日本厚生劳动省统计的关联死亡人数一度达到81人。选购保健品不能只看宣传,要关注原料安全和企业质量记录。

2. 收购与股价变化:私募机构CVC和NSSK正考虑以超过5000亿日元(约215亿元人民币)收购小林制药,消息推动股价一周内上涨超16%,市值约5346亿日元,但仍比2020年巅峰时的1.07万亿日元打了对折。消费者可通过这些信号判断品牌经营是否稳健。

3. 曾经的热销产品也需要理性看待:小林制药靠镇痛消炎剂、退热贴、除臭剂等成为“日本神药”,但丑闻后2026上半年营业利润同比大降67.5%,说明品牌光环不等于长期安全,购买日系药妆和保健食品时应保持谨慎。

总:小林制药从细分市场王者的成功到红曲事件后的信任危机,给品牌商提供了重要的经营教训和策略参考。

1. 小池塘钓大鱼策略:小林制药避开大企业激烈竞争的10亿元体量大池塘,选择1亿元体量的小市场,通过牙线棒、去死皮膏、除臭剂等细分产品获得高市占率和高利润率,并用吸睛包装塑造辨识度。品牌商可以学习在生活小场景中寻找差异化和增量。

2. 品牌信任是生命线:红曲事件导致产品召回、利润受损,两年半后仍有约520名受害者需要补偿,公司被迫把重塑消费者信任列为首要任务,并计划未来3年各投入300亿日元用于研发与设备投资以强化质量安全。品牌商应认识到质量安全一旦失守,挽回代价极大。

3. 渠道与成本风险:日本本土药妆店渠道正在整合,消费者越来越依赖第三方电商平台,叠加瓶子、薄膜等包装材料以及石油化学原料涨价,预计全年营业利润减少20亿日元。品牌商需要提前布局多元渠道,优化产品结构和销售体系,并关注少子高龄化带来的消费需求变化。

总:小林制药的案例既给卖家带来保健品和日系药妆领域的风险警示,也提示了选品和渠道方面的机会。

1. 风险提示:红曲保健品丑闻造成消费者健康损害和品牌信任崩塌,小林制药因回收、广告中止等因素累计影响既有产品销售约184亿日元,并计提红曲相关特别损失约163亿日元。卖家销售同类产品时务必重视质量合规,避免因源头安全问题遭受巨大损失。

2. 需求变化与机会:访日游客消费回暖曾支撑小林制药国内销售,中国内地及香港市场约占其总营收8%;随着日系便利店普及,小包装日用品仍有稳定需求,但消费者越来越习惯在第三方电商平台下单,卖家应抓住电商渠道,并留意日本药妆店整合带来的分销格局变化。

3. 事件应对与可学习点:小林制药计划削减本土及海外约25%的SKU,并出售海外子公司和外部上市公司股份以优化资金配置。卖家可以借鉴其聚焦核心产品、收缩非核心业务的思路,同时关注原材料涨价带来的成本压力,及时调整采购和定价策略。

总:小林制药的轻资产模式和在成本、质量上的应对措施,为工厂理解客户需求和调整自身能力带来几点启示。

1. 代工与合作机会:小林制药将部分生产环节外包,工厂有机会成为这类品牌商的代工伙伴。但品牌商正在削减约25%的SKU,代工需求会随之变化,工厂需要提升生产灵活性和多品种小批量能力。

2. 材料和成本压力:受中东局势影响,瓶子、薄膜等容器包装材料以及酒精类、表面活性剂等石油化学系原料涨价,小林制药预计全年营业利润因此减少20亿日元。工厂应关注上游原料价格波动,与客户协商成本分担机制,并通过包装和工艺改进降低综合成本。

3. 质量安全与设备投资:红曲事件后,小林制药计划未来3年内分别投入300亿日元用于研发与设备投资,强化质量安全。这提示工厂要建立严格的质量追溯和检测体系,尽可能满足客户对合规与安全的高要求,并适时升级设备以承接更高质量的订单。

总:小林制药面临的信任崩塌、成本上升和渠道失效,集中体现了日本老牌消费品牌的典型痛点,也为服务商提供了明确的服务方向。

1. 行业趋势与客户痛点:保健品丑闻导致业绩与信任双降,外部股东频繁施压;同时原材料涨价、本土药妆店渠道整合、消费者转向第三方电商平台,使传统销售体系受阻。服务商可围绕品牌重建、渠道转型和成本控制提供咨询与运营服务。

2. 解决方案需求:小林制药已将重塑消费者信任列为首要任务,计划3年内各投入300亿日元用于研发和设备投资,强化质量安全;同时削减约25%的SKU,出售非核心资产优化资金配置。这些动作背后需要产品结构梳理、质量合规体系搭建、供应链降本等专业支持。

3. 资本与治理服务:私募机构CVC和NSSK提出超过5000亿日元的私有化收购提案,公司需要财务顾问、法律和交易架构支持;外部激进投资者绿洲管理公司通过股东提案和诉讼推动治理改革,也凸显了上市公司在应对激进股东和优化治理方面的服务需求。

总:小林制药的渠道变化和经营困境,显示出品牌对第三方电商平台的依赖增强,平台商在招商和运营中可以找准介入点。

1. 品牌渠道转向线上:文中指出日本本土药妆店渠道正在整合,消费者习惯在第三方电商平台下单,小林制药的产品结构与销售体系亟需重整。平台商可以加强对日系药妆和生活用品品牌的招商,提供线上运营工具和流量入口,帮助品牌触达新消费群体。

2. 帮助品牌优化商品结构:小林制药正计划削减本土及海外约25%的SKU,以缓解成本压力和资源分散问题。平台商可利用销售数据和分析能力,帮助品牌识别高效单品、淘汰低效长尾商品,提升电商渠道的运营效率。

3. 风险规避与信任建设:由于小林制药经历过红曲事件,平台商在引入类似品牌时更应重视审核其质量记录和合规资质,并通过质量标识、售后保障和用户评价机制帮助重建消费者信任,降低平台自身的声誉风险。

总:小林制药从“日本神药”到面临私有化的过程,为研究日本老牌药企困境、家族企业治理及产业转型提供了典型案例。

1. 产业新动向:2024年以来,大正制药和久光制药先后由创始家族主动私有化,这两家也是逾百年历史的家族企业;小林制药则在业绩下滑和股东施压下收到收购提案。这反映出日本老牌药企的黄金时代已经过去,退出公开市场以摆脱短期业绩压力、投入长期战略正在成为一股浪潮。

2. 新问题与政策法规启示:红曲保健品事件造成消费者健康损害甚至死亡,截至2026年8月被认定补偿对象约520人,小林制药被迫退出红曲业务。该事件凸显保健品原料安全、质量追溯、受害者补偿机制和上市企业危机监管的重要性,可作为其他国家完善相关法规的参考。

3. 商业模式与治理研究:小林制药凭借“小池塘钓大鱼”的细分市场策略连续26个财年保持最终利润增长,但红曲事件暴露了内部质量管控和创始家族治理的短板;外部激进投资者绿洲管理公司通过股东提案和诉讼施压,也提示了家族企业权力制衡和董事会独立性的研究价值。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

Overall: This report centers on Kobayashi Pharmaceutical's massive losses, declining performance, and possible acquisition due to the red yeast rice supplement safety scandal. Ordinary consumers can draw several important reminders.

1. Red yeast rice supplements carry health risks: Starting in March 2024, some consumers who took Kobayashi's supplements containing red yeast rice developed kidney disease. By the end of August 2026, about 520 consumers had been certified for compensation, and the number of related deaths counted by Japan's Ministry of Health, Labour and Welfare once reached 81. When choosing supplements, consumers should not just look at marketing claims; they should also pay attention to ingredient safety and the company's quality record.

2. Acquisition and stock price changes: Private equity firms CVC and NSSK are considering acquiring Kobayashi for more than 500 billion yen (about 21.5 billion RMB). The news boosted the stock price by over 16% in one week, giving the company a market capitalization of about 534.6 billion yen, still roughly half of its peak of 1.07 trillion yen in 2020. Consumers can use these signals to judge whether a brand is operating steadily.

3. Even once best-selling products should be viewed rationally: Kobayashi became the "Japanese miracle drug" maker through analgesic anti-inflammatory agents, cooling sheets, deodorants, etc. But after the scandal, its operating profit for the first half of 2026 fell sharply by 67.5% year on year, showing that brand halo does not equal long-term safety. Consumers should remain cautious when buying Japanese drugstore and health products.

Overall: Kobayashi Pharmaceutical's trajectory from niche market champion to the trust crisis after the red yeast rice incident offers important operational lessons and strategic references for brand owners.

1. Fishing for big fish in a small pond: Kobayashi avoided the big pond of 10 billion yen where large companies compete fiercely, and instead selected small markets with a scale of 1 billion yen. Through niche products such as dental floss sticks, callus removers, and deodorants, it achieved high market share and high profit margins, and built distinctiveness with eye-catching packaging. Brand owners can learn to find differentiation and incremental growth in everyday small scenarios.

2. Brand trust is a lifeline: The red yeast rice incident led to product recalls and profit damage. Even after two and a half years, about 520 victims still require compensation. The company has been forced to make restoring consumer trust a top priority and plans to invest 30 billion yen each in R&D and equipment over the next three years to strengthen quality and safety. Brand owners should recognize that once quality and safety fail, the cost of recovery is enormous.

3. Channel and cost risks: Drugstore channels in Japan are consolidating, consumers are increasingly relying on third-party e-commerce platforms, and rising costs of packaging materials such as bottles and films as well as petrochemical feedstocks are expected to reduce full-year operating profit by 2 billion yen. Brand owners should diversify channel coverage in advance, optimize product portfolios and sales systems, and watch shifts in consumer demand caused by a declining birthrate and an aging population.

Overall: The Kobayashi Pharmaceutical case serves as a risk warning for sellers in the supplement and Japanese drugstore beauty categories, while also pointing to opportunities in product selection and channels.

1. Risk reminders: The red yeast rice supplement scandal caused consumer health damage and a collapse of brand trust. Kobayashi's existing product sales were affected by about 18.4 billion yen in total due to recalls and suspended advertising, and it booked special losses of about 16.3 billion yen related to red yeast rice. Sellers offering similar products must prioritize quality and compliance to avoid huge losses caused by upstream safety problems.

2. Demand shifts and opportunities: A recovery in spending by visitors to Japan once supported Kobayashi's domestic sales, while mainland China and Hong Kong accounted for about 8% of its total revenue. As Japanese-style convenience stores expand, small-packaged daily necessities still enjoy stable demand, but consumers are increasingly accustomed to ordering on third-party e-commerce platforms. Sellers should seize e-commerce channels and monitor changes in the distribution landscape caused by drugstore consolidation in Japan.

3. Crisis response and takeaways: Kobayashi plans to cut about 25% of its SKUs domestically and overseas, and to sell stakes in overseas subsidiaries and external listed companies to optimize capital allocation. Sellers can learn from its approach of focusing on core products and shrinking non-core businesses, while also paying attention to cost pressure from raw material price increases and adjusting procurement and pricing strategies in a timely manner.

Overall: Kobayashi's asset-light model and its response to costs and quality offer several lessons for factories in understanding customer needs and adjusting their own capabilities.

1. OEM and partnership opportunities: Kobayashi outsources part of its production, giving factories the opportunity to become OEM partners for such brands. However, as the brand cuts about 25% of its SKUs, OEM demand will change accordingly. Factories need to improve production flexibility and capabilities for high-mix, small-batch production.

2. Material and cost pressures: Affected by Middle East tensions, packaging materials such as bottles and films, as well as petrochemical raw materials including alcohol and surfactants, have risen in price. Kobayashi expects full-year operating profit to decrease by 2 billion yen as a result. Factories should monitor upstream raw material price fluctuations, negotiate cost-sharing mechanisms with customers, and reduce overall costs through packaging and process improvements.

3. Quality and safety, and equipment investment: After the red yeast rice incident, Kobayashi plans to invest 30 billion yen each in R&D and equipment over the next three years to strengthen quality and safety. This reminds factories to build strict quality traceability and testing systems, meet customers' high requirements for compliance and safety as much as possible, and upgrade equipment when appropriate to take on higher-quality orders.

Overall: The collapse of trust, rising costs, and weakening distribution channels confronting Kobayashi highlight typical pain points of established Japanese consumer brands and point to clear service opportunities for providers.

1. Industry trends and client pain points: The supplement scandal has driven down both earnings and trust, with external shareholders repeatedly pressing for change. At the same time, raw material costs have risen, domestic drugstore channels are consolidating, and consumers are shifting to third-party e-commerce platforms, all hindering traditional sales systems. Service providers can offer consulting and operational support for brand rebuilding, channel transformation, and cost control.

2. Demand for solutions: Kobayashi has made restoring consumer trust a top priority, planned to invest 30 billion yen each in R&D and equipment over three years to strengthen quality and safety, while cutting roughly 25% of SKUs and selling non-core assets to optimize capital allocation. These actions require professional support in areas such as product portfolio rationalization, quality and compliance system building, and supply-chain cost reduction.

3. Capital and governance services: Private equity firms CVC and NSSK have proposed a privatization acquisition worth more than 500 billion yen, so the company needs financial advisory, legal, and transaction structuring support. Activist investor Oasis Management has also pushed governance reforms through shareholder proposals and litigation, underscoring the service demand for listed companies in dealing with activist shareholders and improving governance.

Overall: Kobayashi's channel shifts and business difficulties show that brands are becoming more reliant on third-party e-commerce platforms, giving marketplace operators clear entry points for merchant recruitment and operations.

1. Brands shifting channels online: The article notes that domestic drugstore channels are consolidating, consumers are accustomed to ordering on third-party e-commerce platforms, and Kobayashi's product portfolio and sales system urgently need restructuring. Marketplace operators can strengthen recruitment of Japanese drugstore and daily-goods brands, provide online operating tools and traffic entry points, and help brands reach new consumer groups.

2. Helping brands optimize product assortments: Kobayashi is planning to cut about 25% of its SKUs at home and overseas to ease cost pressure and resource fragmentation. Marketplace operators can use sales data and analytics to help brands identify efficient items and phase out inefficient long-tail products, improving the operating efficiency of e-commerce channels.

3. Risk avoidance and trust building: Because Kobayashi experienced the red yeast rice incident, marketplace operators should pay more attention to reviewing the quality records and compliance qualifications of similar brands when onboarding them, and help rebuild consumer trust through quality labels, after-sales guarantees, and user review mechanisms, thereby reducing reputational risk for the platform itself.

Overall: Kobayashi's trajectory from a "Japanese miracle drug" maker to a company facing privatization provides a typical case study for researching the difficulties of established Japanese pharmaceutical companies, family business governance, and industrial transformation.

1. New industry dynamics: Since 2024, Taisho Pharmaceutical and Hisamitsu Pharmaceutical have both been taken private voluntarily by their founding families; both are family businesses with more than a century of history. Kobayashi, meanwhile, has received an acquisition proposal amid declining earnings and shareholder pressure. This reflects that the golden age of established Japanese drugmakers has passed, and exiting public markets to escape short-term earnings pressure and invest in long-term strategy is becoming a wave.

2. New issues and policy/regulatory implications: The red yeast rice supplement incident caused consumer health damage and even deaths. By August 2026, about 520 people had been certified as eligible for compensation, and Kobayashi was forced to exit the red yeast rice business. The incident highlights the importance of raw material safety, quality traceability, victim compensation mechanisms, and crisis regulation of listed companies, and can serve as a reference for other countries improving relevant regulations.

3. Business model and governance research: With its "fishing for big fish in a small pond" niche market strategy, Kobayashi maintained net profit growth for 26 consecutive fiscal years. But the red yeast rice incident exposed weaknesses in internal quality control and founding-family governance. Activist investor Oasis Management's pressure through shareholder proposals and litigation also highlights the research value of checks and balances and board independence in family businesses.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

保健品丑闻爆发两年半后,小林制药要卖身了。

据外媒报道,私募股权机构CVC Capital Partners与日本产业推进机构(NSSK),正在考虑对小林制药株式会社(小林制药)发起私有化收购,潜在要约金额超过5000亿日元(折合人民币约215亿元),小林制药创始家族也可能参与其中。

小林制药通过一则声明确认了这则私有化收购提案,但表示尚未做出任何决定。不过,据知情人士透露,公司及创始家族已聘请银行和财务顾问评估这份提案。

对小林制药来说,这份提案来得算是及时——小林制药曾靠着镇痛消炎剂、退热贴、去鸡皮膏等产品,被称为"日本神药"。尤其是当711、全家、罗森这样日系便利店在国内迅速铺开,小林制药的这些小玩意儿,也逐渐变成了中国人民的快消品。

然而,在2024年3月旗下红曲保健品被曝导致健康损害后,两年多来,这家公司一直困在业绩下滑、股东施压与信任崩塌的漩涡里。

截至9月29日收盘,受收购预期推动,小林制药的股价一周内已涨超16%,市值达到5346亿日元(约合人民币229亿元),基本回到了丑闻爆发前的水平。但比起巅峰时期,这个市值依旧是打了对折——2020年12月,小林制药的市值一度达到1.07万亿日元(约合人民币459亿元)。

无论这次私有化进程是否顺利,属于小林制药等日本老牌药企的黄金时代,也已经过去。

日本土特产,爆雷

虽然看名字是个药企,但小林制药的业务领域其实更接近日用品。

小林制药的产品线,像是一家日本药妆店的浓缩版:药品、口腔护理、食品、香氛、除臭剂、家居用品等。其中,药品主要是眼药水、鼻炎药、去疤药等治疗轻症的药物。而撑起市场辨识度的,还是镇痛消炎剂、暖宝宝与退热贴。

这个业务结构,与小林制药的来时路有关。

1886年,商人小林忠兵卫创立了小林制药的前身“小林盛大堂”。起初,小林盛大堂做的是生活用品、化妆品与药品的经销生意。做经销商利润薄,小林制药很快决定转型做生产商,陆续推出了治疗脚气、脚癣的药剂和头痛药,但并没在市场上砸起水花。这很合理——制药是一门高壁垒生意,研发一款新药动辄10年起,半路出家的小林制药,拿什么和大药企比?

于是小林制药调头回到了自己熟悉的日用品领域,开始在大企业看不上的细分市场发力。

用小林制药的官方说法,这种产品策略叫“在小池塘钓大鱼”:

10亿元体量的市场是大池塘,竞争激烈,不是目标市场。而1亿元体量的小池塘里竞争少,可以获得高市场占有率,确保高利润率。

沿着这个思路,小林制药推出了牙线棒、去死皮膏、防中暑的清凉贴片、专治鞋柜冰箱马桶异味的除臭剂等产品。再配上标志性的吸睛包装,小林制药逐渐成为外国消费者高低得买上几件“日本特产”。

小林制药的这套打法,很长一段时间都很奏效。2023年,小林制药营收1734亿日元(折合人民币约74亿元),国内业务贡献1304亿日元,访日游客的消费回暖是一大助力。海外业务占总营收约24%,中国内地及香港市场合计贡献约135亿日元(约6亿元),占总营收约8%。截至2023年,小林制药已经连续26个财年保持最终利润增长。

绕开巨头,在生活场景的细枝末节里找增量,再将部分生产环节外包,小林制药的“轻生意”本来应该稳定地走下去,却在2024年翻车了。

2024年3月,因为部分服用了公司含红曲成分保健品的消费者出现了肾脏疾病等病症,小林制药对相关产品进行了召回。红曲是用红曲菌发酵米等谷物制成的原料,其中某些成分具有降低胆固醇的作用,因此也被做成了保健品销售。

经过反复调查,截至2024年7月初,日本厚生劳动省统计的、正在调查与红曲产品是否存在因果关系的死亡人数达到81人。同月,小林制药会长(相当于董事长)小林一雅辞任。此后,社长(相当于总裁)小林章浩也辞任。上述两位高管都出身小林制药的创始家族。小林制药也在当年决定退出红曲业务。

红曲事件对小林制药带来的代价是实打实的。截至2025年末,小林制药国内业务营收为1180亿日元,较2023年下降约9.5%。2024年与2025年,红曲产品回收、广告中止等因素累计影响小林制药既有产品销售约184亿日元,公司同期计提的红曲相关特别损失约163亿日元。

老牌药企接连退市

两年半过去,小林制药仍未彻底摆脱红曲事件的阴影。小林制药官网显示,截至2026年8月31日,因红曲事件受到健康损害并被认定为补偿对象的消费者,已达约520人。

2026年上半年,小林制药营收707亿日元,同比增长2.5%,但营业利润仅21亿日元,同比大降67.5%。其中,恢复广告投放后大幅增加的营销费用,对小林制药国内业务的营业利润造成了明显压力。

小林制药的业绩与市场信任都亟需修复。在今年2月公布的计划中,公司将重塑消费者信任列为首要任务,并计划在未来3年内,分别投入300亿日元用于研发与设备投资,将质量安全强化作为重要任务。同时,小林制药开始调整资源结构,计划削减本土及海外约25%的SKU,并在近月来接连出售了海外子公司与持有的外部上市公司股份,以优化资金配置。

内部改革的成效体现需要时间。而作为百年老企业的小林制药,要面对的外部挑战也不小。

受中东局势影响,瓶子、薄膜等容器包装材料,以及酒精类、表面活性剂等石油化学系原料接连涨价。根据小林制药预计,原材料涨价将让公司全年营业利润减少20亿日元。而随着日本本土药妆店渠道的整合、消费者习惯在第三方电商平台下单,以及日益突出的少子高龄化问题,小林制药的产品结构与销售体系也亟需重整。

一系列挑战下,来自外部股东的压力,或许成为了小林制药走向私有化的最后一根稻草。

据彭博社数据,小林制药目前的第一大股东,是总部位于香港的激进投资者绿洲管理公司(Oasis Management),绿洲管理公司目前持股比例为14.4%,而小林制药自身持股4.8%。

自红曲事件爆发以来,绿洲管理公司频繁通过股东提案和诉讼,要求小林制药推进治理改革,并指出小林制药未能充分削弱创始家族的影响力。

在此背景下,小林制药收到了来自NSSK与CVC的私有化提案。如果这一方案最终敲定,小林制药也将加入日本老牌药企退市的浪潮。

2024年以来,大正制药和久光制药已先后完成私有化动作。大正制药旗下拥有能量饮料品牌Lipovitan D(力保健)与感冒药品牌Pabron(百保能),久光制药最为人熟知的产品,则是另一“日本特产”撒隆巴斯。与小林制药类似,这两家公司的发展历史都超过百年,且长期以来由创始人家族掌舵。

不过,大正制药与久光制药退市过程相对从容——两家公司的私有化都由创始人家族主动发起。在退市前营收与净利润都处于双位数增长状态。而且,公司退市的目的,都是摆脱上市状态下的短期业绩压力,将更多资源投入海外业务扩张与渠道转型等长期策略中。

相比之下,在业绩下滑、股东压力与信任危机交织下迎来买家评估的小林制药,处境要困难得多。但无论私有化最终能否落地,小林制药都必须在新的市场环境下转换经营方式,日本老牌药企的黄金时代已经过去。

注:文/李馨婷,文章来源:投中网(公众号ID:China-Venture),本文为作者独立观点,不代表亿邦动力立场。

文章来源:投中网

广告
微信
朋友圈

FAQ回顾

小林制药是一家什么样的公司?

小林制药是创立于1886年的日本百年企业,主营药品、口腔护理、食品、家居用品等,以暖宝宝、退热贴、镇痛消炎剂等产品被称为“日本神药”。其采用“在小池塘钓大鱼”的细分市场策略,2023年营收达1734亿日元,连续26个财年保持最终利润增长。

小林制药为什么会被私有化收购?

2024年3月红曲保健品事件导致小林制药业绩下滑、信任崩塌,叠加股东施压与原材料涨价等挑战。私募股权机构CVC资本与日本产业推进机构(NSSK)提出超过5000亿日元的私有化收购提案,创始家族也可能参与,公司已聘请银行和财务顾问评估该提案。

小林制药红曲保健品事件是什么?

2024年3月,消费者服用小林制药含红曲成分保健品后出现肾脏疾病,公司召回相关产品。截至2024年7月初,日本厚生劳动省统计死亡人数达81人。小林制药随后退出红曲业务,并持续面临召回、广告中止等导致的特别损失,两年多来股价和业绩受到严重影响。

日本老牌药企为何纷纷退市?

2024年以来,大正制药、久光制药已先后完成私有化,小林制药也可能加入这一浪潮。这些发展超过百年的家族药企退市,普遍是为摆脱上市状态下的短期业绩压力,将资源投入海外扩张、渠道转型等长期策略。而小林制药是在业绩下滑和信任危机交织下迎来买家评估,处境更为困难。

小林制药市值经历了怎样的变化?

受收购预期推动,截至2026年9月29日,小林制药市值达5346亿日元(约合人民币229亿元),股价一周内涨超16%,基本回到丑闻爆发前水平。但相较于2020年12月1.07万亿日元(约合人民币459亿元)的巅峰市值,仍打了对折。

这么好看,分享一下?

朋友圈 分享

APP内打开

赞 +1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0